1. pregnant or breast feeding or have plan to become pregnant in 30 days after the administration of study intervention. 2. employees at the investigator's site, of the sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study. 3. currently receiving or received any investigational intervention within 30 days prior to the vaccination of study intervention. 4. administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to vaccination of study intervention. 5. administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the vaccination of study intervention. 6. currently receiving or anticipated to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or \< 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the vaccination of study intervention. 7. currently receiving or anticipated to receive treatment with tumor necrosis factor (tnf)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the vaccination of study intervention. 8. major surgery or any radiation therapy within 12 weeks prior to the vaccination of study intervention. 9. immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia. 10. a history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator). 11. bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. 12. a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (tts), antiphospholipid syndrome, capillary leak syndrome, myocarditis, or pericarditis 13. participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. acute diseases or serious medical conditions include cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, psychiatric condition (e.g. alcoholism, drug abuse, anorexia or severe depression), current severe infections, autoimmune disease, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant. 14. documented sars-cov1 or 2 infection prior to the study intervention. 15. participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the azd1222, mrna-1273 or mvc-cov1901. 16. body (oral, rectal, or ear) temperature ≥ 38.0°c or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the vaccination of study intervention. 17. any condition that is a contraindication to study intervention based on the judgement of the investigator

1. pregnant or breast feeding or have plan to become pregnant in 30 days after the administration of study intervention. 2. employees at the investigator's site, of the sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study. 3. currently receiving or received any investigational intervention within 30 days prior to the vaccination of study intervention. 4. administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to vaccination of study intervention. 5. administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the vaccination of study intervention. 6. currently receiving or anticipated to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or \< 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the vaccination of study intervention. 7. currently receiving or anticipated to receive treatment with tumor necrosis factor (tnf)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the vaccination of study intervention. 8. major surgery or any radiation therapy within 12 weeks prior to the vaccination of study intervention. 9. immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia. 10. a history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator). 11. bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. 12. a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (tts), antiphospholipid syndrome, capillary leak syndrome, myocarditis, or pericarditis 13. participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. acute diseases or serious medical conditions include cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, psychiatric condition (e.g. alcoholism, drug abuse, anorexia or severe depression), current severe infections, autoimmune disease, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant. 14. documented sars-cov1 or 2 infection prior to the study intervention. 15. participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the azd1222, mrna-1273 or mvc-cov1901. 16. body (oral, rectal, or ear) temperature ≥ 38.0°c or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the vaccination of study intervention. 17. any condition that is a contraindication to study intervention based on the judgement of the investigator

pregnant or breast feeding or have plan to become pregnant in 30 days after the administration of study intervention. employees at the investigator's site, of the sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study. currently receiving or received any investigational intervention within 30 days prior to the vaccination of study intervention. administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to vaccination of study intervention. administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the vaccination of study intervention. currently receiving or anticipated to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the vaccination of study intervention. currently receiving or anticipated to receive treatment with tumor necrosis factor (tnf)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the vaccination of study intervention. major surgery or any radiation therapy within 12 weeks prior to the vaccination of study intervention. immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia. a history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator). bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (tts), antiphospholipid syndrome, capillary leak syndrome, myocarditis, or pericarditis participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. acute diseases or serious medical conditions include cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, psychiatric condition (e.g. alcoholism, drug abuse, anorexia or severe depression), current severe infections, autoimmune disease, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant. documented sars-cov1 or 2 infection prior to the study intervention. participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the azd1222, mrna-1273 or mvc-cov1901. body (oral, rectal, or ear) temperature ≥ 38.0°c or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the vaccination of study intervention. any condition that is a contraindication to study intervention based on the judgement of the investigator

pregnant or breast feeding or have plan to become pregnant in 30 days after the administration of study intervention. employees at the investigator's site, of the sponsor or delegate (e.g., contract research organization) who are directly involved in the conduct of the study. currently receiving or received any investigational intervention within 30 days prior to the vaccination of study intervention. administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to vaccination of study intervention. administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the vaccination of study intervention. currently receiving or anticipated to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the vaccination of study intervention. currently receiving or anticipated to receive treatment with tumor necrosis factor (tnf)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the vaccination of study intervention. major surgery or any radiation therapy within 12 weeks prior to the vaccination of study intervention. immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia. a history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator). bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. a history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia, thrombosis with thrombocytopenia syndrome (tts), antiphospholipid syndrome, capillary leak syndrome, myocarditis, or pericarditis participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. acute diseases or serious medical conditions include cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, psychiatric condition (e.g. alcoholism, drug abuse, anorexia or severe depression), current severe infections, autoimmune disease, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant. documented sars-cov1 or 2 infection prior to the study intervention. participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the azd1222, mrna-1273 or mvc-cov1901. body (oral, rectal, or ear) temperature ≥ 38.0°c or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the vaccination of study intervention. any condition that is a contraindication to study intervention based on the judgement of the investigator